MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
IPO Year: 2021
Exchange: NASDAQ
Website: https://mdxhealth.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/31/2024 | $7.00 | Buy | Lake Street |
| 5/31/2023 | $7.00 | Outperform | TD Cowen |
| 7/18/2022 | $18.00 | Outperform | Oppenheimer |
4 - MDxHealth SA (0001872529) (Issuer)
Lake Street initiated coverage of MDxHealth SA with a rating of Buy and set a new price target of $7.00
TD Cowen initiated coverage of MDxHealth SA with a rating of Outperform and set a new price target of $7.00
Oppenheimer resumed coverage of MDxHealth SA with a rating of Outperform and set a new price target of $18.00
6-K - MDxHealth SA (0001872529) (Filer)
6-K - MDxHealth SA (0001872529) (Filer)
6-K - MDxHealth SA (0001872529) (Filer)
6-K - MDxHealth SA (0001872529) (Filer)
20-F - MDxHealth SA (0001872529) (Filer)
SCHEDULE 13G/A - MDxHealth SA (0001872529) (Subject)
6-K - MDxHealth SA (0001872529) (Filer)
6-K - MDxHealth SA (0001872529) (Filer)
SCHEDULE 13G/A - MDxHealth SA (0001872529) (Subject)
SCHEDULE 13G/A - MDxHealth SA (0001872529) (Subject)
IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles across public and private biotech, medtech, health tech, pharma, and wellness companies. His expertise encompasses corporate strategy, M&A, corporate governance, and sales productivity. He's led a $25
Year-over-year Q1 revenues increase by 22% to $24.3 million71% year-over-year improvement in adjusted EBITDA in first quarterConference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 14, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the first quarter ended March 31, 2025. Michael K. McGarrity, CEO of mdxhealth, commented: "mdxhealth delivered a strong first quarter, marked by our 16th consecutive quarter of 20% or greater revenue growth, fueled by continued execution by our team and strong demand for our precision diagnostics. Our expa
Company to Host Conference Call with Live Q&A, May 14, 2025, at 4:30pm ET / 22:30 CET IRVINE, California – April 30, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH), a leading precision diagnostics company, today announced it will release its financial results for the first quarter ended March 31, 2025, after market close on Wednesday, May 14, 2025. Title:Mdxhealth Presents First Quarter 2025 Financial Results andCorporate Update Conference Call and WebcastSpeakers:Michael K. McGarrity, Chief Executive OfficerRon Kalfus, Chief Financial OfficerDate:May 14, 2025Time:4:30pm ET/ 22:30 CETConference Call Dial-in Details:United States: 1-844-825-9789Belgium: 0800 38 961The Netherlands: 0800
Fourth quarter revenue growth of 28% to $24.7 million2024 revenue growth of 28% to $90.0 million68% improvement in adjusted EBITDA in fourth quarterConference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 26, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the fourth quarter and year ended December 31, 2024. Michael K. McGarrity, CEO of mdxhealth, commented: "We are pleased to report another strong quarter and a successful year for mdxhealth, driven by consistent execution and robust demand for our precision diagnostics. Our perfo
Company to Host Conference Call with Live Q&A, February 26, 2025, at 4:30pm ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 12, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH), a leading precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended December 31, 2024, after market close on Wednesday, February 26, 2025. Title:Mdxhealth Presents Fourth Quarter and Full Year 2024 Financial Results andCorporate Update Conference Call and WebcastSpeakers:Michael K. McGarrity, Chief Executive OfficerRon Kalfus, Chief Financial OfficerDate:February 26, 2025Time:4:30pm ET/ 22:30 CETConference Call Dial-in Details:United S
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance IRVINE, CA – January 13, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today reported preliminary fourth quarter and full year 2024 revenues and issued 2025 revenue guidance. The Company expects to report fourth quarter and full year 2024 revenues of approximately $24.7 and $90.0 million, respectively, representing year-over-year growth of 28% for both periods. During the fourth quarter, the Company billed 11,789 tissue-based units and 12,036 liquid-based units, representing growth of 50% and 10%
MDxHealth to Participate in Piper Sandler Healthcare Conference IRVINE, CA – November 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced that Michael K. McGarrity, Chief Executive Officer, will participate in the Piper Sandler 36th Annual Healthcare Conference, which will take place between Dec 3-5, 2024, in New York City. Piper Sandler 36th Annual Healthcare ConferenceFireside discussion: Wednesday, December 4, 3:00-3:25 pm ETWebcast: https://event.webcasts.com/starthere.jsp?ei=1699716&tp_key=9f5393d579 A live webcast of the fireside chat will be accessible on the Investor page of mdxhealth's web
Tissue-based test volumes increase by 36%, liquid-based test volumes by 24% Company raises 2024 revenue guidance to $87-89 million, representing 25% growth Pro-forma cash of $53.5 million Conference call and webcast today at 4:30pm ET IRVINE, CA – November 6, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the third quarter and nine-month period ended September 30, 2024. Michael K. McGarrity, CEO of mdxhealth, commented: "We generated another strong topline performance in the third quarter of 2024, with year-over-year revenue growth of 21%, or 27% when adjusted for a ba
MDxHealth to Present Third Quarter 2024 Financial Resultsand Corporate Update on November 6 Company to Host Conference Call with Live Q&A, November 6, 2024, at 4:30pm ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – October 14, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH), a commercial-stage precision diagnostics company, today announced it will release its financial results for the third quarter ended September 30, 2024, after market close on Wednesday, November 6, 2024. Title:MDxHealth Presents Third Quarter 2024 Financial Results and Corporate Update Conference Call and WebcastSpeakers:Michael K. McGarrity, Chief Executive OfficerRon Kalfus, Chief Financial OfficerDate:November 6,
MDxHealth Announces Pricing of Offering of Ordinary Shares IRVINE, CA, and HERSTAL, BELGIUM – September 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) ("mdxhealth" or the "Company"), a commercial-stage precision diagnostics company, today announced that it has priced a registered public offering of 20,000,000 ordinary shares of the Company without nominal value ("Ordinary Shares") in a registered public offering (the "Offering") at a price to the public of $2.00 per Ordinary Share for total gross proceeds of $40.0 million before deducting commissions and estimated offering expenses. A strategic partner is purchasing 1,500,000 Ordinary Shares in this Offering directly from the Company
IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles across public and private biotech, medtech, health tech, pharma, and wellness companies. His expertise encompasses corporate strategy, M&A, corporate governance, and sales productivity. He's led a $25
Mdxhealth Appoints Sanford J. Siegel, M.D. to Board of Directors IRVINE, CA, and HERSTAL, BELGIUM – July 8, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced the appointment of Sanford J. Siegel, M.D. to its Board of Directors. Dr. Siegel will be taking the seat of Lieve Verplancke M.D., who is stepping down from the Board of mdxhealth. Dr. Siegel has more the 45 years of experience as a practicing urologist and over 35 years of executive leadership experience. Dr. Siegel currently serves as the Chairman of the Board of United Urology Group, having previously served as its Chie
Mdxhealth Announces Resignation of Board Member IRVINE, CA, and HERSTAL, BELGIUM – February 16, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced that Jan Pensaert has stepped down from the Board of Directors of mdxhealth. His resignation was effective as of February 15, 2024. Mr. Pensaert's resignation is not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company. Michael K. McGarrity, CEO of mdxhealth, commented: "On behalf of the Board of Directors and the employees of mdxhealth, I would like to thank Jan for his suppor
Year-over-year Q1 revenues increase by 22% to $24.3 million71% year-over-year improvement in adjusted EBITDA in first quarterConference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 14, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the first quarter ended March 31, 2025. Michael K. McGarrity, CEO of mdxhealth, commented: "mdxhealth delivered a strong first quarter, marked by our 16th consecutive quarter of 20% or greater revenue growth, fueled by continued execution by our team and strong demand for our precision diagnostics. Our expa
Company to Host Conference Call with Live Q&A, May 14, 2025, at 4:30pm ET / 22:30 CET IRVINE, California – April 30, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH), a leading precision diagnostics company, today announced it will release its financial results for the first quarter ended March 31, 2025, after market close on Wednesday, May 14, 2025. Title:Mdxhealth Presents First Quarter 2025 Financial Results andCorporate Update Conference Call and WebcastSpeakers:Michael K. McGarrity, Chief Executive OfficerRon Kalfus, Chief Financial OfficerDate:May 14, 2025Time:4:30pm ET/ 22:30 CETConference Call Dial-in Details:United States: 1-844-825-9789Belgium: 0800 38 961The Netherlands: 0800
Fourth quarter revenue growth of 28% to $24.7 million2024 revenue growth of 28% to $90.0 million68% improvement in adjusted EBITDA in fourth quarterConference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 26, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the fourth quarter and year ended December 31, 2024. Michael K. McGarrity, CEO of mdxhealth, commented: "We are pleased to report another strong quarter and a successful year for mdxhealth, driven by consistent execution and robust demand for our precision diagnostics. Our perfo
Company to Host Conference Call with Live Q&A, February 26, 2025, at 4:30pm ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 12, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH), a leading precision diagnostics company, today announced it will release its financial results for the fourth quarter and full year ended December 31, 2024, after market close on Wednesday, February 26, 2025. Title:Mdxhealth Presents Fourth Quarter and Full Year 2024 Financial Results andCorporate Update Conference Call and WebcastSpeakers:Michael K. McGarrity, Chief Executive OfficerRon Kalfus, Chief Financial OfficerDate:February 26, 2025Time:4:30pm ET/ 22:30 CETConference Call Dial-in Details:United S
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance IRVINE, CA – January 13, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today reported preliminary fourth quarter and full year 2024 revenues and issued 2025 revenue guidance. The Company expects to report fourth quarter and full year 2024 revenues of approximately $24.7 and $90.0 million, respectively, representing year-over-year growth of 28% for both periods. During the fourth quarter, the Company billed 11,789 tissue-based units and 12,036 liquid-based units, representing growth of 50% and 10%
Tissue-based test volumes increase by 36%, liquid-based test volumes by 24% Company raises 2024 revenue guidance to $87-89 million, representing 25% growth Pro-forma cash of $53.5 million Conference call and webcast today at 4:30pm ET IRVINE, CA – November 6, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the third quarter and nine-month period ended September 30, 2024. Michael K. McGarrity, CEO of mdxhealth, commented: "We generated another strong topline performance in the third quarter of 2024, with year-over-year revenue growth of 21%, or 27% when adjusted for a ba
MDxHealth to Present Third Quarter 2024 Financial Resultsand Corporate Update on November 6 Company to Host Conference Call with Live Q&A, November 6, 2024, at 4:30pm ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – October 14, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH), a commercial-stage precision diagnostics company, today announced it will release its financial results for the third quarter ended September 30, 2024, after market close on Wednesday, November 6, 2024. Title:MDxHealth Presents Third Quarter 2024 Financial Results and Corporate Update Conference Call and WebcastSpeakers:Michael K. McGarrity, Chief Executive OfficerRon Kalfus, Chief Financial OfficerDate:November 6,
MDxHealth Reports Q2 and Half Year 2024 Results Year-over-year Q2 revenues increase by 32% to $22.2 millionYear-over-year H1 revenues increase by 34% to 42.0 millionConference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – August 21, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced its financial results for the second quarter and half year ended June 30, 2024. Michael K. McGarrity, CEO of mdxhealth, commented: "Our strong topline growth of 32% for the second quarter reflects our commercial team's execution even against our strongest quarter of 2023 for bo
MDxHealth to Present Second Quarter and First Half 2024 Financial Results and Corporate Update on August 21 Company to Host Conference Call with Live Q&A, August 21, 2024, at 4:30pm ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – August 12, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH), a commercial-stage precision diagnostics company, today announced it will release its financial results for the second quarter and six-month period ended June 30, 2024, after market close on Wednesday, August 21, 2024. Title:MDxHealth Presents Second Quarter and First Half 2024 Financial Results and Corporate Update Conference Call and WebcastSpeakers:Michael K. McGarrity, Chief Executive Off
MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed Year-over-year Q1 revenues increase by 35% to $19.8 millionIncreasing 2024 revenue guidance to $83-85 million, previously $79-81 million Conference call with Q&A today at 08:30 AM ET / 14:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 1, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ:MDXH) (the "Company" or "mdxhealth"), a commercial-stage precision diagnostics company, today announced its financial results for the first quarter ended March 31, 2024 and the closing of a new debt facility with OrbiMed. Michael K. McGarrity, CEO of mdxhealth, commented: "We are pleased to report operating results that demonstrate su
SC 13G - MDxHealth SA (0001872529) (Subject)
SC 13D/A - MDxHealth SA (0001872529) (Subject)
SC 13G - MDxHealth SA (0001872529) (Subject)
SC 13G - MDxHealth SA (0001872529) (Subject)
SC 13G/A - MDxHealth SA (0001872529) (Subject)
SC 13D/A - MDxHealth SA (0001872529) (Subject)
SC 13G/A - MDxHealth SA (0001872529) (Subject)
SC 13D/A - MDxHealth SA (0001872529) (Subject)
SC 13D/A - MDxHealth SA (0001872529) (Subject)
SC 13G/A - MDxHealth SA (0001872529) (Subject)